Nothing Special   »   [go: up one dir, main page]

JPH064669B2 - Polyene substance and obesity function regulator - Google Patents

Polyene substance and obesity function regulator

Info

Publication number
JPH064669B2
JPH064669B2 JP1055862A JP5586289A JPH064669B2 JP H064669 B2 JPH064669 B2 JP H064669B2 JP 1055862 A JP1055862 A JP 1055862A JP 5586289 A JP5586289 A JP 5586289A JP H064669 B2 JPH064669 B2 JP H064669B2
Authority
JP
Japan
Prior art keywords
substance
cells
polyene
mast cell
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP1055862A
Other languages
Japanese (ja)
Other versions
JPH021498A (en
Inventor
和哉 中込
秀興 田中
登 冨塚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute of Advanced Industrial Science and Technology AIST
Original Assignee
Agency of Industrial Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency of Industrial Science and Technology filed Critical Agency of Industrial Science and Technology
Priority to JP1055862A priority Critical patent/JPH064669B2/en
Publication of JPH021498A publication Critical patent/JPH021498A/en
Publication of JPH064669B2 publication Critical patent/JPH064669B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

【発明の詳細な説明】 〔技術分野〕 本発明は、ポリエン物質及び肥満細胞機能調節剤に関す
るものである。
TECHNICAL FIELD The present invention relates to a polyene substance and a mast cell function regulator.

〔従来技術〕[Prior art]

肥満細胞は動物の結合組織及び消化管粘膜内に存在し、
細胞内にケミカルメディエーターと呼ばれる生物活性物
質を含む顆粒を数多く持っている。炎症性反応及びアレ
ルギー反応はともに、刺激を受けた肥満細胞が脱顆粒反
応を起こし、ヒスタミン、セロトニンなどのケミカルメ
ディエーターを放出するところから始まる。免疫グロブ
リンEの受容体を持つ細胞として肥満細胞が注目され、
肥満細胞における刺激の伝達機能及び脱顆粒反応の作用
機作などを解明することがアレルギー反応を理解するこ
とに直接つながるため、肥満細胞の脱顆粒作用及び脱顆
粒抑制作用等の機能調節作用をもつ物質の開発が望まれ
ている。
Mast cells are present in the connective tissues of animals and in the gastrointestinal mucosa,
It has many granules containing biologically active substances called chemical mediators in its cells. Both an inflammatory reaction and an allergic reaction start when stimulated mast cells undergo a degranulation reaction and release chemical mediators such as histamine and serotonin. Mast cells are attracting attention as cells that have receptors for immunoglobulin E,
Since elucidation of the stimulus transmission function and the mechanism of action of degranulation reaction in mast cells directly leads to understanding of allergic reaction, it has function-regulating actions such as degranulation action and degranulation inhibition action of mast cells. Development of substances is desired.

〔発明が解決しようとする問題点〕[Problems to be solved by the invention]

そこで、本発明者らは、このような作用を有する物質の
開発について広く検討を行ったところ、下記一般式で示
される新規なポリエン物質が肥満細胞機能調節作用を有
することをはじめて明らかにし、本発明を完成させた。
Therefore, the present inventors have extensively studied the development of a substance having such an action, and have revealed for the first time that a novel polyene substance represented by the following general formula has a mast cell function-regulating action, Completed the invention.

従って、本発明は新規なポリエン物質及び肥満細胞機能
調節剤を提供することを目的とする。
Therefore, an object of the present invention is to provide a novel polyene substance and a mast cell function regulator.

〔問題点を解決するための手段〕[Means for solving problems]

本発明によれば、下記一般式で示されるポリエン物質及
び肥満細胞機能調節剤が提供される。
According to the present invention, a polyene substance and a mast cell function regulator represented by the following general formula are provided.

前記式中、R1は水素原子又はアルキル基であり、アルキ
ル基としては、メチル、エチル、プロピル等の低級アル
キル基が挙げられる。R2は水素原子又は水酸基である。
R3は水素原子、塩形成性カチオン又はアルキル基であ
る。塩形成性カチオンとしては、ナトリウムやカリウム
等のアルカリ金属、カルシウムやマグネシウム等のアル
カリ土類金属の他、アルミニウム、アンモニウム、有機
アンモニウム等が挙げられる。アルキル基としては、メ
チル、エチル、プロピル等の低級アルキル基が挙げられ
る。
In the above formula, R 1 is a hydrogen atom or an alkyl group, and examples of the alkyl group include lower alkyl groups such as methyl, ethyl and propyl. R 2 is a hydrogen atom or a hydroxyl group.
R 3 is a hydrogen atom, a salt-forming cation or an alkyl group. Examples of the salt-forming cation include alkali metals such as sodium and potassium, alkaline earth metals such as calcium and magnesium, as well as aluminum, ammonium and organic ammonium. Examples of the alkyl group include lower alkyl groups such as methyl, ethyl and propyl.

前記一般式(I)において、R3が水素原子であるポリエン
物質(以下、本物質とも言う)は、ストレプトベルティ
シリウム・ユーロシジカム (Streptoverticillium eurocidicum、IFO No.13491)株
又はストレプトベルティシリウム・アルビレティキュリ
(Streptoverticillium albireticuli、IFO No.12737)株
を、一般培地に培養し、培地中に産生させることができ
る。この場合の培養は、例えば、炭素源としてグルコー
ス、シュークロース、マルトース、デキトリン、澱粉、
グリセリン等を、窒素源としてはペプトン、肉エキス、
酵母エキス、麦芽エキス等を用い、さらに無機塩とし
て、NaCl、K2HPO4Na2HPO4、MgSO4等を加えた中性液体培
地中で、通気、攪拌することにより実施することができ
る。培地のpHは5〜8、好ましくは7付近で培養され
る。培養温度は通常、20〜35℃の範囲であるが、30℃付
近が好ましい。例えばグリコール1.5%、ペプトン0.5%、
肉エキス0.5%、酵母エキス0.5%、NaCl0.5%を含むpH7.0
の液体培地で28℃、40時間培養することにより、本物
質を生産させることができる。
In the general formula (I), a polyene substance in which R 3 is a hydrogen atom (hereinafter, also referred to as this substance) is a Streptoverticillium eurocidicum (IFO No. 13491) strain or Streptoverticillium arubi Reticuli
The (Streptoverticillium albireticuli, IFO No. 12737) strain can be cultured in a general medium and produced in the medium. The culture in this case is performed by, for example, glucose, sucrose, maltose, dextrin, starch as a carbon source,
Glycerin, etc. as the nitrogen source, peptone, meat extract,
It can be carried out by using yeast extract, malt extract and the like, and aerating and stirring in a neutral liquid medium to which NaCl, K 2 HPO 4 Na 2 HPO 4 , MgSO 4 and the like have been added as inorganic salts. The medium is cultured at a pH of 5 to 8, preferably around 7. The culture temperature is usually in the range of 20 to 35 ° C, preferably around 30 ° C. For example, glycol 1.5%, peptone 0.5%,
PH 7.0 containing 0.5% meat extract, 0.5% yeast extract, 0.5% NaCl
This substance can be produced by culturing at 28 ° C. for 40 hours in the above liquid medium.

培養濾液からの本物質の採取は、有機溶媒抽出法、イオ
ン交換樹脂法、及び吸着剤を用いた吸脱着法や、高速液
体ウロマトグラフィー法等を用いて行うことができる。
例えば、培養濾液中に1/10体積量のアンバーライトXAD-
7を加えて時々攪拌しながら室温で約4時間吸着処理を
行った後、アンバーライトXAD-7を濾別し、これを洗浄
後、80%メタノール溶液で溶出処理する。溶出液を減圧
濃縮後、水に再溶解し、pH4.0に調整した後、CM−トヨ
パールイオン交換クロマトグラフィーを行うと、0.05M
酢酸−酢酸アンモニウムによるpHグラジエントによりpH
5.0付近から溶出が始まる。この溶出液をさらにpH9.0に
調整し、DEAE−トヨパールイオン交換クロマトグラフィ
ーを行うとpH7.5付近から溶出が始まる。さらに活性画
分を、MCIゲルCHP-20P吸着カラムに吸着させ、40%アセ
トニトリル溶出画分を分取した後、高速液体クロマトグ
ラフィー(HPLC)を用いることにより本物質を得ることが
できる。
Collection of this substance from the culture filtrate can be carried out by an organic solvent extraction method, an ion exchange resin method, an adsorption / desorption method using an adsorbent, a high performance liquid urography method, or the like.
For example, 1/10 volume of Amberlite XAD- in the culture filtrate.
After adding 7 and adsorbing at room temperature for about 4 hours with occasional stirring, Amberlite XAD-7 is filtered off, washed, and then eluted with 80% methanol solution. The eluate was concentrated under reduced pressure, redissolved in water, adjusted to pH 4.0, and subjected to CM-Toyopearl ion exchange chromatography to give 0.05M.
PH with an acetic acid-ammonium acetate pH gradient
Elution starts from around 5.0. When this eluate is further adjusted to pH 9.0 and subjected to DEAE-Toyopearl ion exchange chromatography, elution begins around pH 7.5. Further, the active fraction is adsorbed on an MCI gel CHP-20P adsorption column, a 40% acetonitrile-eluted fraction is collected, and then this product can be obtained by using high performance liquid chromatography (HPLC).

さらに、本物質は菌体をメタノール等の有機溶媒を用い
る抽出処理した後、ODSカラム等による吸着クロマトグ
ラフィーを用い、溶出画分を濃縮、結晶化等の通常の精
製操作を行うことによっても得ることができる。
Furthermore, this substance can also be obtained by subjecting the bacterial cells to an extraction treatment using an organic solvent such as methanol, and then using adsorption chromatography using an ODS column or the like to concentrate the elution fraction and carry out ordinary purification operations such as crystallization. be able to.

前記、一般式(I)においてR3が塩形成性カチオン及びア
ルキル基を示すものは、一般式(I)においてR3が水素原
子を示す物質に対し、それぞれ対応するカチオンを含む
塩基及びエステル化剤を常法により反応させることによ
って得ることができる。
In the above general formula (I), R 3 represents a salt-forming cation and an alkyl group, a substance having a cation corresponding to R 3 in the general formula (I) is a base and esterification containing a corresponding cation. It can be obtained by reacting the agent by a conventional method.

また、本物質は、通常用いられる化学合成法もしくは酵
素を用いる合成法によっても得ることができる。ポリエ
ン物質あるいはそれに類するものとマイコースもしくは
マイコサミンなどを用いることにより本物質を合成する
ことができる。
The substance can also be obtained by a commonly used chemical synthesis method or a synthetic method using an enzyme. This substance can be synthesized by using a polyene substance or the like and mycose or mycosamine.

〔実施例〕〔Example〕

次に、本発明を実施例によりさらに詳細に説明する。 Next, the present invention will be described in more detail with reference to examples.

実施例1 グルコース1.5%、ペプトン0.5%、肉エキス0.5%、酵素エ
キス0.5%、NaCl0.5%を含むpH7.5%の液体培地100mlを500
mlの坂口フラスコに分注し、120℃、20分間滅菌する。
この培地に放線菌ストレプトベルティシリウム・ユーロ
シジカム株の斜面寒天培地より1白金耳量を接種し、28
℃、3日間往復しんとう培養を行った。この培養液と同
組成の培地20を30用ジャーファーメンターに仕込
み、ストレプトベルティシリウム・ユーロシジカム株の
前培養液300mlをこの培地に移し、28℃、200回転、通気
量毎分10で40時間培養を行った。培養終了後、7000
回転の連続遠心を行うことにより、菌体と培養濾液とを
分離し、黒かっ色の培養濾液18を得た。この培養濾液
の肥満細胞脱顆粒抑制活性は642,500ユニットであっ
た。
Example 1 500 ml of 100 ml of pH 7.5% liquid medium containing glucose 1.5%, peptone 0.5%, meat extract 0.5%, enzyme extract 0.5%, and NaCl 0.5%
Dispense into a ml Sakaguchi flask and sterilize at 120 ° C for 20 minutes.
This medium was inoculated with 1 platinum loop amount from a slope agar medium of Streptoverticillium eurosidicum strain of Streptomyces sp.
Reciprocating agitation culture was performed at 3 ° C for 3 days. A medium 20 having the same composition as this culture solution was charged into a jar fermenter for 30 and 300 ml of a preculture solution of the Streptoverticillium eurosidicum strain was transferred to this medium, and at 28 ° C., 200 rpm, and an aeration rate of 10 minutes, 40 hours. Culture was performed. 7,000 after culture
The cells were separated from the culture filtrate by continuous rotation centrifugation to obtain a black-brown culture filtrate 18. The mast cell degranulation inhibitory activity of this culture filtrate was 642,500 units.

実施例2 実施例1で得た菌体に5倍量のメタノールを加えて攪拌
後、室温にて放置した。時々攪拌しながら24時間置いた
後、菌体を濾別後、メタノール抽出液を同容量の水と混
合して、ODS吸着カラム(日本ミリポア製、カラム体積7
78ml、メタノール/水=1/1にて平衡化)に吸着させ
た。溶出液(メタノール/水=2/1)を用いてI,II及
びIIIの画分を順次得、濃縮、再結晶操作により、各画
分に対応する本物質NO.1:5.0mg、NO.2:8.7mg及びN
O.3:100mgを得た。
Example 2 To the cells obtained in Example 1 was added 5 times the amount of methanol, the mixture was stirred, and then allowed to stand at room temperature. After leaving for 24 hours with occasional stirring, the bacterial cells were filtered off, and the methanol extract was mixed with an equal volume of water to obtain an ODS adsorption column (Nihon Millipore, column volume 7
78 ml, equilibrated with methanol / water = 1/1). Fractions I, II and III were sequentially obtained using the eluate (methanol / water = 2/1), and concentrated and recrystallized to give the corresponding substance NO.1: 5.0 mg, NO. 2: 8.7 mg and N
O. 3: 100 mg was obtained.

実施例3 (1)実施例1で得られた培養濾液のうち5中に、その1
/10体積に相当する吸着剤アンバーライトXAD-7を加え、
時々振とうしながら4時間室温にて吸着処理した。吸引
濾過におり、吸着剤を濾別し、精製水で洗浄した後、吸
着剤体積の2倍量に相当する20%メタノール水溶液で洗
浄した。その後、吸着剤体積の3倍量に相当する80%メ
タノール水溶液で溶出させ、溶出液を減圧濃縮した後、
精製水に溶解させた。ほぼ100%近い活性が回収できた。
Example 3 (1) 1 out of 5 of the culture filtrates obtained in Example 1
/ 10 volume of adsorbent Amberlite XAD-7 is added,
Adsorption treatment was performed at room temperature for 4 hours with occasional shaking. In suction filtration, the adsorbent was filtered off, washed with purified water, and then washed with a 20% aqueous methanol solution corresponding to twice the adsorbent volume. Then, elute with 80% aqueous methanol solution corresponding to 3 times the adsorbent volume, and concentrate the eluate under reduced pressure.
It was dissolved in purified water. Almost 100% of the activity could be recovered.

(2)次に、CM−トヨパール650Mカラム〔東ソー製、カラ
ム体積533ml、0.05M酢酸−酢酸アンモニウム(pH4.0)で
平衡化〕にpH4.0に調整した試料溶液を吸着させ、0.05M
酢酸−酢酸アンモニウム(pH6.0)で溶出させた。活性画
分は溶出後のpH5.0から溶出してきた。活性画分の肥満
細胞脱顆粒抑制活性は25,250ユニットであった。
(2) Next, a CM-Toyopearl 650M column (manufactured by Tosoh, column volume 533 ml, equilibrated with 0.05 M acetic acid-ammonium acetate (pH 4.0)) was adsorbed with a sample solution adjusted to pH 4.0, and 0.05 M was added.
It was eluted with acetic acid-ammonium acetate (pH 6.0). The active fraction began to elute at pH 5.0 after elution. The mast cell degranulation inhibitory activity of the active fraction was 25,250 units.

(3)さらに上記(2)の活性画分を、pH9.0に調整した後、D
EAE−トヨパール650Mカラム〔東ソー製、カラム体積179
ml、0.05M酢酸アンモニウム−アンモニア水でpH9.0に平
衡化〕に、吸着させ、0.05M酢酸アンモニウム−アンモ
ニア水(pH7.5)で溶出させた。この活性画分の活性は、1
6,500ユニットであった。
(3) After further adjusting the active fraction of (2) above to pH 9.0,
EAE-Toyopearl 650M column [Tosoh, column volume 179
ml, equilibrated to pH 9.0 with 0.05 M ammonium acetate-ammonia water], and eluted with 0.05 M ammonium acetate-ammonia water (pH 7.5). The activity of this active fraction is 1
It was 6,500 units.

(4)さらに、MCIゲル(CHP-20P、三菱化成製)を充填した
吸着カラム(カラム体積40ml)に、前記(3)で得られた
活性画分を吸着させ、20%アセト−トリル水溶液で洗浄
後、40%アセトニトリル水溶液で溶出させ、減圧濃縮し
て白色物質を得た。
(4) Furthermore, the active fraction obtained in (3) above was adsorbed to an adsorption column (column volume 40 ml) packed with MCI gel (CHP-20P, manufactured by Mitsubishi Kasei), and 20% aceto-tolyl aqueous solution was used. After washing, it was eluted with 40% aqueous acetonitrile solution and concentrated under reduced pressure to obtain a white substance.

得られた物質をメタノールに溶解させ、HPLCにて分離し
た。この場合の分離条件は次の通りである。
The obtained substance was dissolved in methanol and separated by HPLC. The separation conditions in this case are as follows.

カラム :ヌクレオシル5C8充填、直径10mm 長さ250mm 使用溶媒:アセトニトリル/酢酸アンモニウム 緩衝液(0.01M、pH5.0)=35/65 流 速:4ml/分 検 出:紫外波長350nmにおける吸光度測定 試料濃度:0.2mg/ml 注入量 :200μl/回 上記条件にて物質NO.1、、NO.2及びNO.3に該当する画分
を分取し、減圧濃縮して物質NO.1:1.1mg、NO.2:1.5mg
及びNo.3:10mgを得た。
Column: Nucleosyl 5C8 packed, diameter 10 mm, length 250 mm Solvent used: acetonitrile / ammonium acetate buffer (0.01 M, pH 5.0) = 35/65 Flow rate: 4 ml / min Detection: Absorbance measurement at UV wavelength 350 nm Sample concentration: 0.2 mg / ml Injection volume: 200 μl / times Under the above conditions, the fractions corresponding to substance NO.1, NO.2 and NO.3 were collected and concentrated under reduced pressure to obtain substance NO.1: 1.1 mg, NO .2: 1.5 mg
And No. 3: 10 mg were obtained.

実施例4 (1)物質NO.1、、NO.2及びNO.3をそれぞれ約1.5mgを正確
に計りとり、微量元素分析を行った。炭素、水素及び窒
素の含有率は、物質NO.1:C=57.59%、H=7.61%、N=1.
76%と、物質NO.2:C=57.70%、H=7.57%、N=1.65%、
物質NO.3:C=58.86%、H8.10%、N=1.86%と測定され、
それぞれ、C39H63O17N(理論値C=57.27%、H=7.76%、
N=1.71%)C40H65O17N(理論値:C=57.75%、H=7.87
%、N=1.68%)、C40H65O16N(C=58.88%、H=8.03%、N
=1.72%)の組成をもつものであると明らかになった。
Example 4 (1) About 1.5 mg of each of the substances NO.1, NO.2 and NO.3 was accurately measured and trace element analysis was performed. The contents of carbon, hydrogen and nitrogen are as follows: NO.1: C = 57.59%, H = 7.61%, N = 1.
76% and substance NO.2: C = 57.70%, H = 7.57%, N = 1.65%,
Material NO.3: C = 58.86%, H8.10%, N = 1.86%,
C 39 H 63 O 17 N (theoretical value C = 57.27%, H = 7.76%,
N = 1.71%) C 40 H 65 O 17 N (Theoretical value: C = 57.75%, H = 7.87
%, N = 1.68%), C 40 H 65 O 16 N (C = 58.88%, H = 8.03%, N
= 1.72%).

(2)物質NO.1、、NO.2及びNO.3について、その質量分析を
行った。FAB-MS法による測定結果は、物質NO.1は、(M+
H)+=782.36となり、C39H59O15N(M=781.39)と判明し
た。物質NO.2は、(M+H)+=796.47となり、C40H61O15N(M
=795.40)と判明した。物質NO.3は、(M+H)+=780.45と
なり、C40H61O14N(M=799.41)と判明した。元素分析法
の値はそれぞれ2水塩(2H2O)であると推定された。
(2) Mass spectrometry was performed on the substances NO.1, NO.2 and NO.3. FAB-MS measurement results show that substance No. 1 is (M +
H) + = 782.36, which proved to be C 39 H 59 O 15 N (M = 781.39). Material NO.2 becomes (M + H) + = 796.47, and C 40 H 61 O 15 N (M
= 795.40). The substance NO.3 became (M + H) + = 780.45, which was found to be C 40 H 61 O 14 N (M = 799.41). The elemental analysis values were estimated to be dihydrate (2H 2 O), respectively.

(3)物質NO.1、、NO.2及びNO.3をメタノールに溶解し紫外
線吸収スペクトル分析を行った。その結果は、物質NO.
1、NO.2及びNO.3はいずれも302nm、316nm、331nm及び34
9nmに極大波長を示すペンタエン構造であることが明ら
かとなり、吸収の強さはE(1%、MeOH)で表わすと、物質N
O.1では、398(302nm)、844(316nm)、1375(331nm)及び13
88(349nm)となり、物質NO.2では、344(302nm)、700(316
nm)、1122(331nm)及び1144(349nm)となり、物質NO.3で
は、362(302nm)、760(316nm)、1210(331nm)及び1232(34
9nm)となった。
(3) The substances NO.1, NO.2 and NO.3 were dissolved in methanol and subjected to ultraviolet absorption spectrum analysis. The result is substance NO.
1, NO.2 and NO.3 are all 302 nm, 316 nm, 331 nm and 34
It was clarified that it has a pentaene structure with a maximum wavelength at 9 nm, and the absorption intensity is E (1%, MeOH).
In O.1, 398 (302 nm), 844 (316 nm), 1375 (331 nm) and 13
88 (349 nm), and for substance No. 2, 344 (302 nm), 700 (316 nm)
nm), 1122 (331 nm) and 1144 (349 nm) .For substance NO.3, 362 (302 nm), 760 (316 nm), 1210 (331 nm) and 1232 (34 nm).
9 nm).

(4)物質NO.1、、NO.2及びNO.3をそれぞれ約10μg計りと
り、臭化カリウムと混合して錠剤をつくり、KBrタブレ
ット法による赤外線吸収スペクトル分析法を行った。そ
の結果、各物質とも、3380cm-1、1700cm-1、1560cm-1
1390cm-1、1070cm-1及び1005cm-1に吸収を示し、ポリエ
ン物質としての特徴を示していた。
(4) About 10 μg of each of the substances NO.1, NO.2 and NO.3 was weighed and mixed with potassium bromide to prepare tablets, and infrared absorption spectrum analysis by the KBr tablet method was performed. As a result, for each substance, 3380 cm -1 , 1700 cm -1 , 1560 cm -1 ,
1390 cm -1, an absorption in 1070 cm -1 and 1005cm -1, showed the characteristics of a polyene material.

(5)物質NO.1、、NO.2及びNO.3をそれぞれ重水素置換ジメ
チルホルムアミド(DMF-d)もしくは重水素置換ジメチル
スルホキシド(DMSO-d)に溶解して核磁気共鳴スペクトル
を行った。1H核磁気共鳴スペクトル、13C核磁気共鳴ス
ペクトル、13C-DEPT測定及び1H-1Hシフト相関二次元核
磁気共鳴スペクトル分析を行い、各物質の構造は前記一
般式(I)において、物質NO.1の場合、R1=H、R2=OH、R3
=H、物質NO.2の場合、R1=CH3、R2=OH、R3=H、物質N
O.3の場合、R1=CH3、R2=H、R3=Hを示すものであるこ
とを決定した。
(5) Substances NO.1, NO.2 and NO.3 were dissolved in deuterium-substituted dimethylformamide (DMF-d) or deuterium-substituted dimethylsulfoxide (DMSO-d), respectively, and nuclear magnetic resonance spectra were performed. . 1 H nuclear magnetic resonance spectrum, 13 C nuclear magnetic resonance spectrum, 13 C-DEPT measurement and 1 H- 1 H shift correlation two-dimensional nuclear magnetic resonance spectrum analysis, the structure of each substance in the general formula (I), In the case of substance NO.1, R 1 = H, R 2 = OH, R 3
= H, substance NO.2, R 1 = CH 3 , R 2 = OH, R 3 = H, substance N
In the case of O.3, it was determined that R 1 = CH 3 , R 2 = H, and R 3 = H.

実施例5 (1)ウィスター系雌性ラット(体重150〜250g)を脱血致
死させ、腹腔内にタイロード液を20ml注入し、腹部を約
2分間軽くマッサージした。開腹後覆水を採取し、4℃
にて150×g、10分間の条件で遠心分離し、沈澱する細
胞を集めた。この細胞をタイロード液2mlに懸濁させ、
比重1.068に調整した牛血清アルブミン含有生理食塩水4
mlに重層し、4℃、100×gの条件で12分間遠心分離
後、沈澱する細胞を集めた。タイロード液で2回洗浄し
た後、0.2%牛血清アルブミンを含むタイロード液に液に
肥満細胞が約106個/mlとなるように懸濁させ、肥満細
胞浮遊液を得た。
Example 5 (1) Female Wistar rats (body weight 150 to 250 g) were killed by exsanguination, 20 ml of Tyrode's solution was intraperitoneally injected, and the abdomen was gently massaged for about 2 minutes. After laparotomy, cover water and collect at 4 ℃
Were centrifuged at 150 xg for 10 minutes to collect the precipitated cells. Suspend these cells in 2 ml of Tyrode's solution,
Saline containing bovine serum albumin adjusted to a specific gravity of 1.068 4
The cells were layered on top of each other, and centrifuged at 4 ° C. and 100 × g for 12 minutes, and then the precipitated cells were collected. After washing twice with Tyrode's solution, the solution was suspended in Tyrode's solution containing 0.2% bovine serum albumin so that mast cells were about 10 6 cells / ml to obtain a mast cell suspension.

(2)被験化合物を含む生理食塩水20μlと肥満細胞浮遊
液20μlを10分間37℃にて反応させ、最終濃度1μg/
mlとなるようにコンパウンド48/80溶液10μlを加え、
さらに10分間反応させた。反応後1分間氷冷した後、1,
500×g、4分間の条件で遠心し、上澄と細胞とを分離し
た。上澄に含まれるヒスタミンをOndaらのHPLC法(Hiro
chima J.Med.Sci,第27巻、93〜97ページ、1987年によ
り)定量することにより脱顆粒を測定した。この場合、
肥満細胞脱顆粒抑制活性は以下の式より算出した。
(2) 20 μl of physiological saline containing the test compound and 20 μl of mast cell suspension were reacted at 37 ° C. for 10 minutes to give a final concentration of 1 μg /
Add 10 μl of compound 48/80 solution to make up to ml,
The reaction was continued for another 10 minutes. After the reaction was cooled in ice for 1 minute, 1,
The supernatant was separated from the cells by centrifugation at 500 xg for 4 minutes. Histamine contained in the supernatant was analyzed by the Onda et al. HPLC method (Hiro
Chima J. Med. Sci, 27, 93-97, 1987) was used to measure degranulation. in this case,
The mast cell degranulation inhibitory activity was calculated by the following formula.

A;細胞をコンパウンド48/80とのみ反応させ た時に遊離されたヒスタミン量 B;被験化合物を細胞と反応させた後、コンパウンド48
/80を加えてさらに反応させた時 に遊離されたヒスタミン量 C;細胞を緩衝液(もしくは生理食塩水)とのみ 反応させた時に遊離されたヒスタンミン量 脱顆粒誘発剤としては、コンパウンド48/80(シグマ社
製)の他、コンカナバリンA、イオノフォアA23187はじ
め一般に知られている任意の薬剤を用いることができ
る。
A: Amount of histamine released when cells were reacted only with compound 48/80 B; Compound 48 was reacted with the test compound and then reacted with compound 48/80
/ 80 added histamine amount when further reacted C; Histamine amount released when cells were reacted only with buffer (or physiological saline) Compound 48/80 as a degranulation inducer In addition to (manufactured by Sigma), concanavalin A, ionophore A23187 and any other generally known drug can be used.

被験化合物の濃度を種々変えて測定を行い、本測定系で
1μg/mlのコンパウンド48/80により誘発される肥満細
胞脱顆粒を50%抑制する化合物の濃度〔IC50〕値を
求めた。また、コンパウンド48/80の存在しない状態
や、コレステロールを添加した状態など各種の状態や、
コレステロールを添加した状態など各種の条件下で本物
質を肥満細胞に対する機能調節作用の測定も合せて行
い、その結果は以下に示すように、本物質には、強い肥
満細胞機能調節作用をもつことが認められた。
The concentration of the test compound was changed variously, and the concentration [IC 50 ] value of the compound that inhibits 50% of mast cell degranulation induced by 1 μg / ml of compound 48/80 in this measurement system was determined. Also, various conditions such as the absence of compound 48/80, the condition of adding cholesterol,
Measurement of the function-regulating action of this substance on mast cells under various conditions such as the addition of cholesterol was also performed, and the results show that this substance has a strong mast-cell function regulating action. Was recognized.

なお、本測定系で1μg/mlコンパウンド48/80により
誘発される肥満細胞脱顆粒作用を50%抑制する化合物の
濃度を1単位/ml〔1ユニット/ml〕とした。
The concentration of the compound that suppresses 50% of the mast cell degranulation action induced by 1 μg / ml compound 48/80 in this assay system was 1 unit / ml [1 unit / ml].

(3)1mg/mlのコンパウンド48/80の誘発する肥満細胞脱
顆粒作用に対して物質NO.1、NO.2及びNO.3の示した作用
は次の通りであった。
(3) The effects of substances NO. 1, NO. 2 and NO. 3 on the mast cell degranulation effect induced by 1 mg / ml of compound 48/80 were as follows.

(3)−(i) 物質NO.1、NO.2及びNO.3は低濃度領域では肥満細胞脱顆
粒抑制作用を示し、そのIC50値は、物質NO.1:3.6μg
/ml、物質NO.2:1.8μg/ml、物質NO.3:1.0μg/ml
であった。
(3)-(i) Substances NO.1, NO.2 and NO.3 show mast cell degranulation inhibitory action in the low concentration region, and its IC 50 value is substance NO.1: 3.6 μg
/ Ml, substance NO.2: 1.8 μg / ml, substance NO.3: 1.0 μg / ml
Met.

(3)−(ii) 物質NO.1、NO.2及びNO.3は高濃度領域では単独で肥満細
胞脱顆粒作用を示し、本作用は、反応液のカルシウムイ
オン濃度を約1mM以上にした時に発現し、反応液のカル
シウムイオン濃度が0に近い時は発現しないというカル
シウムイオン依存性を示した。
(3)-(ii) Substances NO.1, NO.2 and NO.3 showed mast cell degranulation action alone in the high concentration region, and this action increased the calcium ion concentration of the reaction solution to about 1 mM or more. There was a calcium ion dependency that it was sometimes expressed and was not expressed when the calcium ion concentration of the reaction solution was close to zero.

(3)−(iii) 反応液にコレステロールを一定濃度(約2μg/ml)以上
加えることにより、上記(3)−(i)及び(3)−(ii)の作用
はコレステロールに対して濃度依存的に減少した。
(3)-(iii) The action of (3)-(i) and (3)-(ii) above depends on the concentration of cholesterol by adding cholesterol to the reaction solution at a certain concentration (about 2 μg / ml) or more. Decreased.

実施例6 物質NO.1を100mg計りとり、ジメチルスルホキシド2mlに
溶解した後、無水メタノール0.2mlを加えて希釈した。
0.3モル濃度のジアゾメタンを含むテトラヒドロフラン1
mlをこれに加えて4℃にて約2分間反応させ、エステル
化を行った。反応液に無水エチルエーテル20mlを加えて
沈殿する物質を遠心にて集め、少量の無水エチルエーテ
ルにて洗浄後、同溶媒にて再結晶化操作を行い、物質N
O.1のメチルエステル(前記一般式(I)においてR1=C
H3、R2=H、R3=CH3を示すもの)、72mgを得た。
Example 6 100 mg of the substance NO.1 was weighed and dissolved in 2 ml of dimethyl sulfoxide, and then 0.2 ml of anhydrous methanol was added to dilute it.
Tetrahydrofuran containing 0.3 molar diazomethane 1
Esterification was performed by adding ml to this and reacting at 4 ° C. for about 2 minutes. 20 ml of anhydrous ethyl ether was added to the reaction mixture, and the precipitated substance was collected by centrifugation, washed with a small amount of anhydrous ethyl ether, and recrystallized in the same solvent to give substance N.
The methyl ester of O.1 (in the general formula (I), R 1 ═C
H 3 , R 2 = H, R 3 = CH 3 ), 72 mg were obtained.

メチルエステルの同定は質量分析及び核磁気共鳴スペク
トル分析により行った。
The methyl ester was identified by mass spectrometry and nuclear magnetic resonance spectroscopy.

〔発明の効果〕〔The invention's effect〕

以上のように、本発明により、特定のポリエン物質が肥
満細胞機能調節作用を有することが明らかにされた。
As described above, according to the present invention, it was revealed that a specific polyene substance has a mast cell function regulating action.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 FI 技術表示箇所 C12R 1:01) ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 5 Identification code Office reference number FI technical display location C12R 1:01)

Claims (2)

【特許請求の範囲】[Claims] 【請求項1】下記一般式で示されるポリエン物質。 (式中、R1は水素原子又はアルキル基、R2は水素原子又
は水酸基、R3は水素原子、塩形成性カチオン又はアルキ
ル基を示す)
1. A polyene substance represented by the following general formula. (In the formula, R 1 represents a hydrogen atom or an alkyl group, R 2 represents a hydrogen atom or a hydroxyl group, R 3 represents a hydrogen atom, a salt-forming cation or an alkyl group)
【請求項2】請求項1のポリエン物質からなる肥満細胞
機能調節剤
2. A mast cell function regulator comprising the polyene substance according to claim 1.
JP1055862A 1988-03-09 1989-03-08 Polyene substance and obesity function regulator Expired - Lifetime JPH064669B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP1055862A JPH064669B2 (en) 1988-03-09 1989-03-08 Polyene substance and obesity function regulator

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP63-55580 1988-03-09
JP5558088 1988-03-09
JP1055862A JPH064669B2 (en) 1988-03-09 1989-03-08 Polyene substance and obesity function regulator

Publications (2)

Publication Number Publication Date
JPH021498A JPH021498A (en) 1990-01-05
JPH064669B2 true JPH064669B2 (en) 1994-01-19

Family

ID=26396468

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1055862A Expired - Lifetime JPH064669B2 (en) 1988-03-09 1989-03-08 Polyene substance and obesity function regulator

Country Status (1)

Country Link
JP (1) JPH064669B2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU655327B2 (en) * 1991-10-21 1994-12-15 Symbiosis Corporation Double acting, dual pivot disposable endoscopic surgical instruments
US6302616B1 (en) 1999-09-01 2001-10-16 Olympus Optical Co., Ltd. Rotation mechanism including rotation shaft and fixed member with welding structure, and producing method of the same

Also Published As

Publication number Publication date
JPH021498A (en) 1990-01-05

Similar Documents

Publication Publication Date Title
EP0273388A2 (en) Sialic acid derivatives having active carbonyl group
JPH03130299A (en) Peptide compound and its preparation, and use thereof
JPH064669B2 (en) Polyene substance and obesity function regulator
JPH05247078A (en) Sugar compound, sialic acid-containing sugar chain biosyhnthesis inhibitor, its production, and new intermediate
Syed et al. 9-BBN as a convenient protecting group in functionalisation of hydroxylysine
JP3024864B2 (en) Ellagic acid glycoside and method for producing the same
JP3110474B2 (en) Oligosialyl-1,2-dialkyl-Sn-glycerol and synthetic intermediates thereof
Igarashi et al. Resormycin, a Novel Herbicidal and Antifungal Antibiotic Produced by a Strain of Streptomyces platensis II. Structure Elucidation of Resormycin
JPH11269178A (en) Production of pyridinium compound, and compound therefor
US5152999A (en) Liposome preparation
CA1285936C (en) 3-acylamino-3-deoxyallose derivatives
JPH06157394A (en) Method for synthesizing Benastatin C and D
JP3134010B2 (en) Desalanine benanomycin A derivatives and methods for their production
JPH0415770B2 (en)
JP2578044B2 (en) Phenylalanine-glycine derivative, method for producing the same, and antitumor agent containing the derivative
RU2304583C1 (en) Method for synthesis di- and triaminochlorines
JPH0559046A (en) Immunomodulator
JPH0635467B2 (en) Novel glycosylation method
JP4334194B2 (en) Echinasaidin 786 and method for obtaining the same
WO1992020646A1 (en) Novel quaternary ammonium salts, process for obtaining same and pharmaceutical compositions containing them
JP2001509777A (en) Preparation of glucosaminylmuramic acid derivative
JP3209791B2 (en) Oxazoline derivative and method for producing the same
JP3026041B2 (en) hCG-related 9-saccharide hapten
JPH0429356B2 (en)
JP4523781B2 (en) 2 "-hydroxynicotianamine and method for producing the same.

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term